<DOC>
	<DOCNO>NCT00375284</DOCNO>
	<brief_summary>This trial 6-week , double-blind , randomize , active placebo-controlled parallel-group study primary objective comparison start dos pramipexole fixed-dose ( 0.25 mg daily ) pramipexole titrated-dose ( 0.125 mg qd 1 week , 0.25 mg qd remain 5 week ) placebo evaluate efficacy safety treat RLS symptom patient diagnose idiopathic RLS . The secondary objective study assess onset action symptomatic relief RLS pramipexole daily assessment PGI modify IRLS two interval first 2 week ( Days 2 , 3 4 Days 9 , 10 , 11 ) assessment IRLS , PGI CGI-I Weeks 1 , 2 , 4 6 ( CGI-I additionally Day 3 ) .</brief_summary>
	<brief_title>A 6 Week Trial Study Efficacy Safety Starting Dose 0.25 mg Pramipexole ( Mirapex ) Patients With RLS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>1 . Written inform consent consistent ICHGCP local IRB/IEC requirement obtain prior study procedure perform ability willingness comply study treatment regimen attend study assessment . 2 . Male female outpatient 18 80 year age . 3 . Diagnosis idiopathic RLS accord clinical RLS criterion revise IRLSSG collaboration U.S.A. National Institutes Health [ P0303355 ] . All four criterion must present fulfil diagnosis RLS : An urge move leg , usually accompany cause uncomfortable unpleasant sensation leg . ( Sometimes urge move present without uncomfortable sensation sometimes arm body part involve addition leg ) . The urge move unpleasant sensation begin worsen period rest inactivity lie sit . The urge move unpleasant sensation partially totally relieved movement , walk stretch , least long activity continue . The urge move unpleasant sensation worse even night day occur even night . ( When symptom severe , worsen night may noticeable must previously present ) . 4 . RLS symptoms present least 2 3 day per week last 3 month . 5 . IRLS rating scale score &gt; 15 baseline ( Visit 2 ) . 1 . Women childbearing potential ( i.e. , premenopausal woman , postmenopausal woman le 6 month last menses ) use clinical trial adequate method contraception : double barrier protection ( e.g. , diaphragm condom spermicide ) , intrauterine device , hormonal therapy ( oral , injectable , subcutaneous ) , partner surgical sterilization . 2 . Any woman childbearing potential negative pregnancy test screening . 3 . Breastfeeding woman . 4 . Concomitant previous pharmacologic therapy RLS follow : Any intake dopamine agonist within 14 day prior baseline ( Visit 2 ) . Any intake Ldopa within 14 day prior baseline ( Visit 2 ) . Any intake Ldopa prior baseline visit , augmentation RLS symptom observe . Unsuccessful prior treatment nonergot dopamine agonist ( e.g. , pramipexole , ropinirole ) . 5 . All treatment less 14 day baseline ( Visit 2 ) concomitant treatment medication dietary supplement could significantly influence RLS symptom , e.g. , dopaminergic ( levodopa dopamine agonist ) antidopaminergic drug , nonselective MAO inhibitor , sympathomimetics , neuroleptic , antidepressant , hypnotic , benzodiazepine , antiepileptic , opioids , clonidine , ferrous salt , magnesium , folic acid , vitamin B12 , antihistaminics , lithium , metoclopramide . 6 . Withdrawal symptoms medication must present baseline ( Visit 2 ) . 7 . Previous pramipexole nonresponders indication RLS . 8 . Patients know hypersensitivity pramipexole component investigational product placebo tablet . 9 . Confirmed diagnosis diabetes mellitus require insulin therapy . 10 . Any following lab result screen : Patients clinically significant abnormality laboratory parameter screen investigator discretion . Haemoglobin ( Hb ) low limit normal ( LLN ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>